EphA3 directed CAR-T cells for treatment of tumors
US12139544B2 · kind B2 · utility
0Cited by
5References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2020 |
| Grant date | Nov 12, 2024 |
| Priority date | — |
| Expiry date | Jan 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides chimeric antigen receptors (CARs) targeting human EphA3 and dual targeting CARs that bind to human EphA3 and to human mutant epidermal growth factor receptor variant III (EGFRvIII). This invention also relates to CAR-T cells comprising the provided CARs or the dual targeting CARs. Methods for treating a solid tumor cancer by administering the CARs are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.